Sym022 (anti-LAG-3) was evaluated as a single agent or in combination with sym021 (anti-PD-1) in phase 1 trials for solid tumors or lymphomas (NCT03311412, NCT03489369, and NCT03489343) (Lakhani et al., 2020). Here, LAG3 is linked to lymphoma.